Edition:
United States

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

17.53USD
22 Feb 2019
Change (% chg)

$0.27 (+1.56%)
Prev Close
$17.26
Open
$17.38
Day's High
$17.54
Day's Low
$17.07
Volume
104,673
Avg. Vol
118,897
52-wk High
$34.55
52-wk Low
$16.57

Select another date:

Tue, Dec 4 2018

Revance Therapeutics' Botox rival succeeds in late-stage trial

A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

UPDATE 2-Revance Therapeutics' Botox rival succeeds in late-stage trial

Dec 4 A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.

Revance Therapeutics' frown lines treatment succeeds in late-stage trial

Dec 4 Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

Select another date: